Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease. The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase.
The first patient has been recruited for a UK-wide trial into tackling one of the most disabling complications of Parkinson's disease, led by the Royal United Hospitals Bath NHS Foundation Trust and the University of Bristol.
Improving staff training in care homes and reducing reliance on harmful medications saves thousands of pounds per year, as well as improving quality of life and reducing agitation in dementia, new research has demonstrated.
It will test whether a commonly prescribed dementia drug could prevent debilitating falls for people with the disease. Falls are a frequent complication of Parkinson's, which affect around 60 percent of the 127,000-people diagnosed with the condition each year.
Researchers from the Indiana University Center for Aging Research and the Regenstrief Institute have performed the first study conducted in the United States under real-world conditions comparing patient adherence and tolerability to a class of drugs known as cholinesterase inhibitors.
The withdrawal of donepezil from patients with Alzheimer’s disease as they reach the moderate-to-severe stages of the disease doubles their risk of being placed in a nursing home within the first 12 months, secondary analysis of the DOMINO-AD trial indicates.
Medications commonly used to treat dementia could result in harmful weight loss, according to UC San Francisco researchers, and clinicians need to account for this risk when prescribing these drugs to older adults, they said.
Eli Lilly and Company and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced new data showing that knowledge of amyloid status as determined by Florbetapir F 18 Injection imaging altered diagnosis and management in the majority of patients being studied.
The US Food and Drug Administration has approved a higher dose of Exelon Patch (rivastigmine transdermal system) for the treatment of people with mild to moderate Alzheimer's disease.
Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University of Jerusalem, today announced that it has participated in a U.S. $3 million financing round of Avraham Pharmaceuticals Ltd. together with Pontifax, Clal Biotechnology Industries (CBI), Technion Research and Development Foundation Ltd. (TRDF), Professor Marta Weinstock-Rosin and others.
Blood flow abnormalities found in the brains of veterans with Gulf War illness have persisted 20 years after the war, and in some cases have gotten worse, according to a new study published online in the journal Radiology.
AB Science SA, a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces the publication of results from the first human phase 2 study of masitinib carried-out in the treatment of Alzheimer's disease.
Research on a drug commonly prescribed to Alzheimer's disease patients is helping neuroscientists at the University of California, Berkeley, better understand perceptual learning in healthy adults.
Forest Laboratories, Inc. and Merz Pharmaceuticals GmbH announced today that NAMENDA XR(TM) (memantine hydrochloride) was approved by the U.S. Food and Drug Administration for the treatment of moderate to severe dementia of the Alzheimer's type. NAMENDA XR is a 28 mg once-daily extended-release formulation of NAMENDA.
There is no scientific proof that patients with moderate or severe Alzheimer's disease benefit from drugs containing the agent memantine. This is the conclusion in the final report that the Institute for Quality and Efficiency in Health Care (IQWiG) published in September 2009.
People taking one of several drugs commonly prescribed to treat Alzheimer's disease are more likely to be hospitalized for a potentially serious condition called bradycardia than patients not taking these medications.
Thomas Shea, Ph.D, and his team of scientists, tested the effects of MemoryXL previously shown to improve cognitive performance in Alzheimer's disease on adults without dementia.
Side effects associated with several commonly-prescribed dementia drugs may be putting elderly Canadians at risk, says Queen's University Geriatrics professor Sudeep Gill.
Whether people with Alzheimer's disease benefit in the long term from non-drug treatment interventions remains an unanswered question.
Cholinesterase inhibitors, used to treat cognitive symptoms of Alzheimer's disease, are also a safe and effective alternative therapy for the behavioral and psychological symptoms of dementia, according to a study that appears in the December 2008 edition of Clinical Interventions in Aging.
Older nursing home residents who took medications for dementia and incontinence at the same time had a 50 percent faster decline in function than those who were being treated only for dementia, according to a study from researchers at Wake Forest University School of Medicine and colleagues.